26,811 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by Fideuram Intesa Sanpaolo Private Banking S.P.A.

Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 26,811 shares of the medical research company’s stock, valued at approximately $15,536,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. High Note Wealth LLC increased its position in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares in the last quarter. Beacon Financial Strategies CORP acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Olistico Wealth LLC acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. HFM Investment Advisors LLC grew its position in Thermo Fisher Scientific by 341.7% in the fourth quarter. HFM Investment Advisors LLC now owns 53 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 41 shares in the last quarter. Finally, JPL Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the third quarter worth approximately $28,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Royal Bank Of Canada set a $490.00 price target on shares of Thermo Fisher Scientific and gave the stock a “sector perform” rating in a research report on Thursday, May 14th. Stifel Nicolaus decreased their price target on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Finally, DZ Bank assumed coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $616.10.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $448.34 on Wednesday. The business’s fifty day moving average price is $483.39 and its 200 day moving average price is $540.37. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99. The stock has a market capitalization of $166.61 billion, a PE ratio of 24.65, a price-to-earnings-growth ratio of 1.96 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same period last year, the business posted $5.15 earnings per share. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were paid a $0.47 dividend. The ex-dividend date was Friday, March 13th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.